Combined 18F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Signal Intensity of High B-value Diffusion-weighted Imaging for the Detection of Prostate Cancer
Background: Diffusion-weighted imaging (DWI) is a main component of multiparametric MRI for prostate cancer detection. Recently, high b value DWI has gained more attention because of its capability for tumor characterization. Objective: To assess based on histopathological findings of transrectal ultrasound (TRUS)-guided prostate biopsy as a reference, an...
متن کاملAssociation between Human Papillomavirus Infection and Risk of Prostate Cancer
Human papillomavirus (HPV) is one of the most common causes of sexually transmitted diseases worldwide and is the etiological agent of cervical and other anogenital malignancies. Since HPVs have been shown to possess oncogenic potential, an association between HPV infection and prostatic cancer (PCa) has been suggested. There are conflicting reports on the impact of HPV infection on the deve...
متن کاملCaveolin-1 as a potential high-risk prostate cancer biomarker.
Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. I...
متن کاملFDA Approves 18F-Fluciclovine and 68Ga-DOTATATE Products.
T hrough its Priority Review mechanism, the U.S. Food and Drug Administration (FDA) recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The first, approved on May 27, was Axumin (18F-fluciclovine) injection, indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men with elevated levels of prostate-specific antigen (PSA) foll...
متن کاملCombined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
BACKGROUND To report the outcomes of patients treated with combined iodine-125 (I-125) brachytherapy and external beam radiotherapy (EBRT) for high-risk prostate cancer. METHODS Between 2003 and 2009, I-125 permanent prostate brachytherapy plus EBRT was performed for 206 patients with high-risk prostate cancer. High-risk patients had prostate-specific antigen ≥ 20 ng/mL, and/or Gleason score ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2017
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.117.198598